Shieh Yueh Yang

Designing optical-fiber modulators by using magnetic fluids.

To reduce interface loss between optical fibers and devices in telecommunication systems, the development of an optical-fiber-based device that can be fused directly with fibers is important. A novel optical modulator consisting of a bare fiber core surrounded by magnetic fluids instead of by a SiO2 cladding layer is proposed. Applying a magnetic field raises the refractive index of the magnetic fluid. Thus we can control the occurrence of total reflection at the interface between the fiber core and the magnetic fluid when light propagates along the fiber. As a result, the intensity of the outgoing light is modulated by variation in field strength. Details of the design, fabrication, and working properties of such a modulator are presented.

Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease

A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimers disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n=66), mild cognitive impairment (MCI, n=22), very mild dementia (n=23), and mild-to-serve dementia, all due to AD (n=22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.

Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease

Neurofibrillary tangles are associated with cognitive dysfunction, and hippocampal atrophy with increased CSF tau markers. However, the plasma tau levels of Alzheimers disease (AD) have not been well studied. We investigated plasma tau by using an immunomagnetic reduction assay in 20 patients with mild cognitive impairment (MCI) due to AD, 10 early AD dementia, and 30 healthy elders (HE). All received a 3D‐brain MRI scan and a set of cognitive function test. We explored their relationships with both brain structure and cognitive functions. Images were analyzed to determine the brain volumes and gray matter densities. Patients with MCI or early AD had significantly increased plasma tau levels compared with HE. Plasma tau levels were negatively associated with the performance of logical memory, visual reproduction, and verbal fluency; also negatively associated with volume of total gray matter, hippocampus, amygdala; and gray matter densities of various regions. Regression analyses indicated that logical memory explained 0.394 and hippocampus volume predicted .608 of the variance of plasma tau levels, both P < 0.001. Education years were negatively associated with the gray matter densities of the supramarginal (r = −0.407), middle temporal gyrus (r = −0.40) and precuneus (r = −0.377; all P < 0.05) in HE; and negatively associated with plasma tau levels in patients (r = −0.626). We propose that plasma tau may serve as a window to both structure and function of the brain. Higher education is a protective factor against AD and is associated with lower plasma tau levels in patients. Hum Brain Mapp 35:3132–3142, 2014.

Biofunctionalized Magnetic Nanoparticles for Specifically Detecting Biomarkers of Alzheimer’s Disease in Vitro

Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimers disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ∼10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimers disease from human blood plasma.

Ex vivo magnetofection with magnetic nanoparticles: a novel platform for nonviral tissue engineering.

Several methods have been described to introduce DNA expression vectors into mammalian cells both in vitro and in vivo. Each system has benefits and limitations, and to date there is still no ideal method for gene transfer. In this study, we introduced a novel method of gene transfer by using Fe3O4 nanoparticles. The magnetic nanoparticles composed of Fe3O4, and the transfected genes used are Lac Z and enhanced green fluorescence protein gene (EGFG). Four different groups of preparations included in this study were homemade liposome-enveloped EGFP-DNA/Fe3O4, homemade liposome EGFP-DNA gene without magnetic Fe3O4 nanoparticles, lipofectamine 2000-enveloped EGFP-DNA, and EGFP-DNA gene only. Mice osteoblast and He99 lung cancer cell line were used as host cells for gene transfection. The time-dependent EGFP gene expression was monitored and analyzed. The results showed that the diameter of the complex was less than 100 nm. There was no cytotoxicity observed at any of the magnetic Fe3O4 nanoparticle concentrations tested. In the presence of magnetic field, the liposome-enveloped EGFP-DNA/Fe3O4 complex exhibited a much higher efficiency for transfecting EGFP-DNA into osteoblast cells under external magnetic fields. The gene can be transfected into cells with an aid of magnetic vectors and magnetic force. Under a gradient magnetic field, the efficiency of magnetofection is enhanced as compared to that without magnetic field.

Tunable diffraction of magnetic fluid films and its potential application in coarse wavelength-division multiplexing

When an external magnetic field is applied parallel to the film surface of a magnetic fluid film, a high-quality one-dimensional periodic chain structure is formed when the field strength reaches a certain level. With a periodic chain structure in the magnetic fluid film, an incident light is diffracted onto the magnetic thin film. The results show that the one-dimensional periodic chain structure in the magnetic fluid film can serve as an optical grating. Further investigations reveal the feasibility of developing tunable coarse wavelength-division multiplexing by utilizing a periodic chain structure.

Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease

Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimers pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimers disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received (11)C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92%, and the specificity was 100%; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84%, and the specificity was 100%. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R(2) 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain.

Characterization of tumors using high-Tc superconducting quantum interference device-detected nuclear magnetic resonance and imaging

The characterization of cancerous livers in rats using nuclear magnetic resonance and magnetic resonance imaging (NMR/MRI) based on high-Tc superconducting quantum interference devices (SQUIDs) is presented. The T1−1 were observed to be 6.5±0.5u2002s−1 for controlled livers and 2.85±0.2u2002s−1 for cancerous livers, which indicate that the T1 can be used to distinguish the cancerous tissues from controlled liver tissues. The intensity ratio for tap water, cancerous tissue, and controlled tissue, respectively, is 1:1.15:0.56 at TBp=1u2002s. The SQUID-detected NMR/MRI exhibits potential applications in research and clinics.

Longitudinal relaxation time detection using a high-Tc superconductive quantum interference device magnetometer

The parameters to optimize the measurement of longitudinal relaxation time detection using a high-Tc superconductive quantum interference device magnetometer are investigated. These parameters include the prepolarization field, Bp, the prepolarization time, TBp, and the delay time, Td, to turn on pulses after turning off the prepolarization field. Furthermore, the decreasing of magnetization with the increasing Td of the applied pulse was analyzed to determine the longitudinal relaxation time. We estimated the longitudinal relaxation time to be 2.11±0.04u2002s and 2.29±0.04u2002s, respectively, for water determined from nuclear magnetic resonance signals as a function of TBp and Td at 24u2009°C in a measuring field of 95u2002μT. The data are consistent with the derived longitudinal relaxation time of water measured from the increase of magnetization with the duration of the polarizing field.

Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles

Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was used as a target biomolecule. The signals for AFP solutions of various concentrations, or with interfering materials, were detected via IMR. These samples were also used for characterizing the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The results of assaying AFP level with IMR and ELISA were compared. The detection threshold for assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, and definitely suppresses false negative. For the interfering materials noted commonly in serum such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no detectable interfering effect when assaying AFP with IMR. Several serum samples from normal people and liver-tumor-bearing patients were used for the detections of AFP concentration via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as achieving high-sensitive and high-specific assay for AFP.